Mefloquine Contraindications and Safety Considerations for Malaria Prophylaxis

Contraindications

Patients with a history of seizures or epilepsy should not receive mefloquine, according to the British Medical Journal and CDC (MMWR) recommendations. [1][2]3
Individuals with serious psychiatric disorders (e.g., depression, anxiety, psychosis) are contraindicated for mefloquine use, as advised by the British Medical Journal and CDC (MMWR). [1][2][3][4][5][6]7
Known hypersensitivity to mefloquine is an absolute contraindication per CDC (MMWR) guidance. [4][5][6][7]
Pregnancy, women of child‑bearing potential not using reliable contraception, and lactating persons should avoid mefloquine; contraception must be continued for two months after the last dose (CDC, MMWR). [4][6][8][7]
Children weighing less than 15 kg are generally excluded from mefloquine prophylaxis in older guidelines, although newer pharmacokinetic data suggest possible use in smaller children (CDC, MMWR). [4][5][6][7]
Concurrent use of β‑blockers or other drugs that affect cardiac conduction is contraindicated (CDC, MMWR). [4][5][6][7]
Patients with clinically significant liver impairment should not be prescribed mefloquine (British Medical Journal). [1][2]3
Occupations requiring fine motor coordination and spatial discrimination (e.g., airline pilots) are advised against mefloquine because of neuro‑cognitive risk (CDC, MMWR). [4][5][6][7]

Approximately 70 % of neuropsychiatric side‑effects (e.g., abnormal dreams, anxiety, depressed mood) occur within the first three weekly doses of mefloquine (British Medical Journal). [1][2]3

Starting prophylaxis one week before departure establishes the weekly dosing habit and allows early detection of intolerable side‑effects while the traveler is still at home with access to medical care (British Medical Journal; CDC, MMWR). [1][2][3][9]10
Continuation of mefloquine for four weeks after leaving the endemic area is essential because the drug does not eradicate hepatic‑stage parasites; this post‑travel period prevents the majority of breakthrough infections (British Medical Journal). [1][2]3

Mefloquine remains highly effective against chloroquine‑resistant Plasmodium falciparum malaria and is recommended for high‑risk regions (British Medical Journal). [1][2]3
In regions with documented mefloquine resistance (notably parts of Southeast Asia), doxycycline is the preferred chemoprophylactic alternative (British Medical Journal). [1][2]3

For pregnant travelers to chloroquine‑resistant areas, no fully effective alternative to mefloquine exists; avoidance of travel is advised when possible (CDC, MMWR). [4][6][8][7]
If travel is unavoidable, chloroquine with standby Fansidar (pyrimethamine‑sulfadoxine) may be considered, acknowledging its lower efficacy (CDC, MMWR). [9][10]

All facts are drawn from cited CDC (MMWR) recommendations and BMJ clinical evidence.